Table 1.
Clinicopathologic characteristics, demographics, and values for 838 EOC patients.
| Age (years) | Median: 55; range: 21–79 |
| BMI (kg/m2) | Median: 23; range: 15–47 |
| Menopausal status | |
| Yes | 505 (60.3%) |
| No | 333 (39.7%) |
| Histology | |
| Serous | 599 (71.5%) |
| Mucous and others | 231 (28.5%) |
| Differentiation | |
| G1-2 | 420 (50.1%) |
| G3 | 418 (49.9%) |
| FIGO stage (2009) | |
| I-II | 243 (29.0%) |
| III-IV | 595 (71.0%) |
| With lymphadenectomy | 631 (75.2%) |
| Pelvic | 527 (83.5%) |
| Para-aortic + pelvic | 104 (16.5%) |
| Removed lymph nodes | Median: 25; range: 12–57 |
| Lymph nodes metastasis | |
| No | 642 (76.6%) |
| Yes | 196 (23.4%) |
| Residual disease | |
| <1 cm | 631 (75.3%) |
| ≥1 cm | 207 (24.7%) |
| Ascites volume (mL) | Median: 1000; range: 0–7000 |
| ≤1000 | 591 (70.5%) |
| >1000 | 247 (29.5%) |
| Serum CA125 (U/mL) | Median: 675; range: 23–7400 |
| ≤675 | 521 (62.2%) |
| >675 | 317 (37.8%) |
| Tumor-stroma ratio (TSR) | |
| Stroma-poor (TSR < 50%) | 575 (68.6%) |
| Stroma-rich (TSR ≥ 50%) | 263 (31.4%) |